# APOGEE THERAPEUTICS INC (APGE)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/APGE/

- Reporting holders: 291
- Reported value: $10.0B
- Shares held by institutions: 74,196,079 of 75,339,499 outstanding
- Held through calls: 0.4%
- Held through puts: 1.6%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Venrock Adviser, LLC](https://holderbook.com/funds/1615982-venrock-adviser-llc/) | $1.1B | 8,493,321 | 34.2% | 12 |
| [HBK INVESTMENTS L P](https://holderbook.com/funds/1011443-hbk-investments-l-p/) | $756.6M | 5,700,000 | 3.7% | 1 |
| [BlackRock, Inc.](https://holderbook.com/funds/2012383-blackrock-inc/) | $730.9M | 5,507,032 | 0.0% | 8 |
| [STATE STREET CORP](https://holderbook.com/funds/93751-state-street-corp/) | $610.0M | 4,595,486 | 0.0% | 12 |
| [VANGUARD CAPITAL MANAGEMENT LLC](https://holderbook.com/funds/2100119-vanguard-capital-management-llc/) | $341.4M | 2,572,119 | 0.0% | 2 |
| [FMR LLC](https://holderbook.com/funds/315066-fmr-llc/) | $330.9M | 2,493,137 | 0.0% | 12 |
| [Balyasny Asset Management L.P.](https://holderbook.com/funds/1218710-balyasny-asset-management-l-p/) | $287.4M | 1,665,102 | 0.4% | 2 |
| [MERCER GLOBAL ADVISORS INC /ADV](https://holderbook.com/funds/853758-mercer-global-advisors-inc-adv/) | $249.9M | 1,882,566 | 0.2% | 7 |
| [Driehaus Capital Management LLC](https://holderbook.com/funds/938206-driehaus-capital-management-llc/) | $231.0M | 1,740,101 | 1.3% | 12 |
| [GOLDMAN SACHS GROUP INC](https://holderbook.com/funds/886982-goldman-sachs-group-inc/) | $224.8M | 1,693,341 | 0.0% | 12 |
| [GLAZER CAPITAL, LLC](https://holderbook.com/funds/1076809-glazer-capital-llc/) | $217.8M | 1,641,042 | 5.4% | 1 |
| [Paradigm Biocapital Advisors LP](https://holderbook.com/funds/1855655-paradigm-biocapital-advisors-lp/) | $209.2M | 1,576,385 | 3.9% | 10 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](https://holderbook.com/funds/2100121-vanguard-portfolio-management-llc/) | $202.9M | 1,528,750 | 0.0% | 2 |
| [MILLENNIUM MANAGEMENT LLC](https://holderbook.com/funds/1273087-millennium-management-llc/) | $199.3M | 1,491,404 | 0.1% | 11 |
| [Pentwater Capital Management LP](https://holderbook.com/funds/1425851-pentwater-capital-management-lp/) | $189.1M | 1,425,000 | 1.2% | 1 |
| [MORGAN STANLEY](https://holderbook.com/funds/895421-morgan-stanley/) | $188.7M | 1,421,681 | 0.0% | 12 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $174.6M | 1,314,868 | 0.0% | 12 |
| [PERCEPTIVE ADVISORS LLC](https://holderbook.com/funds/1224962-perceptive-advisors-llc/) | $173.6M | 1,308,113 | 2.6% | 12 |
| [Jupiter Topco LLC](https://holderbook.com/funds/2146052-jupiter-topco-llc/) | $158.4M | 1,193,626 | 0.1% | 1 |
| [BANK OF AMERICA CORP /DE/](https://holderbook.com/funds/70858-bank-of-america-corp-de/) | $149.5M | 1,126,139 | 0.0% | 12 |
| [Affinity Asset Advisors, LLC](https://holderbook.com/funds/1773195-affinity-asset-advisors-llc/) | $131.0M | 987,000 | 5.9% | 12 |
| [First Light Asset Management, LLC](https://holderbook.com/funds/1600004-first-light-asset-management-llc/) | $123.5M | 930,289 | 7.5% | 3 |
| [T. Rowe Price Investment Management, Inc.](https://holderbook.com/funds/1897612-t-rowe-price-investment-management-inc/) | $101.2M | 762,183 | 0.1% | 5 |
| [Kryger Capital LLC](https://holderbook.com/funds/2123957-kryger-capital-llc/) | $98.6M | 742,555 | 5.6% | 1 |
| [Qube Research & Technologies Ltd](https://holderbook.com/funds/1729829-qube-research-technologies-ltd/) | $87.6M | 659,678 | 0.1% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 291 | $10.0B |
| Q1 2026 | 228 | $6.8B |
| Q4 2025 | 208 | $5.4B |
| Q3 2025 | 175 | $2.4B |
| Q2 2025 | 183 | $2.6B |
| Q1 2025 | 171 | $2.3B |
| Q4 2024 | 158 | $2.6B |
| Q3 2024 | 139 | $3.3B |
| Q2 2024 | 138 | $2.1B |
| Q1 2024 | 139 | $3.5B |
| Q4 2023 | 85 | $1.2B |
| Q3 2023 | 73 | $848.7M |